Cardiac involvement in seronegative immune-mediated necrotizing myopathy
DOI:
https://doi.org/10.32818/reccmi.a9n2a19Keywords:
inflammatory myopathy, necrotizing myopathy, extramuscular myopathy, myocarditisAbstract
We present the case of a 43-year-old patient with weakness in the lower limbs that had been going on for
months, associated with dysphagia and severe weight loss, with elevated serum creatine kinase and an electrophysiological study compatible with inflammatory myopathy, with a pathological diagnosis of immune-mediated necrotizing myopathy (IMNM). After starting treatment, the patient presented symptoms of acute heart
failure after entering atrial fibrillation, showing biventrivular dysfunction and data of myocardial infiltration on cardioMRI.
Downloads
Metrics
References
Pinal-Fernandez I, Casal-Dominguez M, Mammen AL. Immune-mediated necrotizing myopathy. Curr Rheumatol Rep. 2018; 20(4): 21. doi: https://doi. org/10.1007/s11926-018-0732-6 (último acceso jul. 2024). DOI: https://doi.org/10.1007/s11926-018-0732-6
Liu M, Lin Y, Qiao L, Chen J, Shi Q. Corrigendum: Characteristics of cardiac involvement in immune-mediated necrotizing myopathy. Front Immunol. 2023; 14: 1233453. doi: https://doi.org/10.3389/fimmu.2023.1233453 (últi¬mo acceso jul. 2024). DOI: https://doi.org/10.3389/fimmu.2023.1233453
Goyal NA. Immune-mediated myopathies. Continuum (Minneap Minn). 2019; 5(6): 1564-1585. doi: https://doi.org/10.1212/CON.0000000000000789 (último acceso jul. 2024). DOI: https://doi.org/10.1212/CON.0000000000000789
Allenbach Y, Benveniste O. Peculiar clinicopathological features of immune-mediated necrotizing myopathies. Curr Opin Rheumatol. 2018; 30(6): 655- 663. doi: https://doi.org/10.1097/BOR.0000000000000547 (último acceso jul. 2024). DOI: https://doi.org/10.1097/BOR.0000000000000547
Watanabe Y, Uruha A, Suzuki S, Nakahara J, Hamanaka K, Takayama K, Suzuki N, Nishino I. Clinical features and prognosis in anti-SRP and an¬ti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry. 2016; 87(10): 1038-1044. doi: https://doi.org/10.1136/jnnp-2016-313166 (últi¬mo acceso jul. 2024). DOI: https://doi.org/10.1136/jnnp-2016-313166
Zhang L, Zhu H, Yang P, Duan X, Wei W, Wu Z, et al. Chinese rheumatism data center-myositis registry (CRDC-MYO). Myocardial involvement in idiopathic inflammatory myopathies: a multi-center cross-sectional study in the CR¬DC-MYO Registry. Clin Rheumatol. 2021; 40(11): 4597-4608. doi: https://doi. org/10.1007/s10067-021-05828-y (último acceso jul. 2024). DOI: https://doi.org/10.1007/s10067-021-05828-y
Tamura T, Miyajima K,Watanabe K, Ito K, Kin F, Okazaki A, et al. An autop¬sy case of antibody-negative immune-mediated necrotizing myopathy with severe cardiac involvement. Intern Med. 2021. 60(19): 3113-3119. doi: https://doi.org/10.2169/internalmedicine.6355-20 (último acceso ago. 2024). DOI: https://doi.org/10.2169/internalmedicine.6355-20
Tsang D, Malladi CL, Patel K, Bajaj P. Seronegative immune-mediated ne¬crotising myopathy complicated by fulminant myocarditis resulting in car¬diogenic shock and cardiac arrest. BMJ Case Rep. 2022; 15(4): e248535. doi: https://doi.org/10.1136/bcr-2021-248535 (último acceso jul. 2024). DOI: https://doi.org/10.1136/bcr-2021-248535
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Irati de Urrutia-Undabarrena, Georgina Romero-Marín, Josefa Andrea Aguilar-García
![Creative Commons License](http://i.creativecommons.org/l/by-nc-nd/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.